Names | |
---|---|
IUPAC name
(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
| |
Other names
L-tyrosyl-L-prolyl-L-tryptophyl-L-threonine
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C29H35N5O7 | |
Molar mass | 565.618 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Hemorphin-4 is an endogenous opioid peptide of the hemorphin family which possesses antinociceptive properties and is derived from the β-chain of hemoglobin in the bloodstream.[1][2] It is a tetrapeptide with the amino acid sequence Tyr-Pro-Trp-Thr. Hemorphin-4 has affinities for the μ-, δ-, and κ-opioid receptors that are in the same range as the structurally related β-casomorphins, although affinity to the κ-opioid receptor is markedly higher in comparison.[3] It acts as an agonist at these sites.[4] Hemorphin-4 also has inhibitory effects on angiotensin-converting enzyme (ACE),[5] and as a result, may play a role in the regulation of blood pressure.[3] Notably, inhibition of ACE also reduces enkephalin catabolism.[6]